Drugs / Griffithsin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02875119 | Oct 2017 → Jul 2018 | HIV infectious disease | Population Council | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Griffithsin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02875119 ↗ |
| Known as | GRFT | “Griffithsin (GRFT) is a non-ARV lectin with potent anti-HIV activity.” PMID 35051209 ↗ Jan 2022 |
| Known as | PC-6500 | “A Phase 1 Trial to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PC-6500 (Griffithsin [GRFT] in a Carrageenan Gel) in Healthy Women” NCT02875119 ↗ |
| Action | Inhibit | “GRFT inhibited entry of pseudo-particles typed with ANDV envelope glycoprotein into host cells” PMID 33251157 ↗ Nov 2020 |
| Route | Other | “after vaginal administration” PMID 35051209 ↗ Jan 2022 |